ET8 Stock Overview
A specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
COSCIENS Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.42 |
| 52 Week High | CA$9.36 |
| 52 Week Low | CA$2.22 |
| Beta | 2.16 |
| 1 Month Change | -3.20% |
| 3 Month Change | -9.70% |
| 1 Year Change | -61.32% |
| 3 Year Change | -91.85% |
| 5 Year Change | -96.79% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ET8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.0% | -12.3% | -0.6% |
| 1Y | -61.3% | -15.3% | 14.8% |
Return vs Industry: ET8 underperformed the German Biotechs industry which returned -15.3% over the past year.
Return vs Market: ET8 underperformed the German Market which returned 14.8% over the past year.
Price Volatility
| ET8 volatility | |
|---|---|
| ET8 Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: ET8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ET8's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Gilles Gagnon | www.cosciensbio.com |
COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.
COSCIENS Biopharma Inc. Fundamentals Summary
| ET8 fundamental statistics | |
|---|---|
| Market cap | €10.07m |
| Earnings (TTM) | -€22.19m |
| Revenue (TTM) | €4.62m |
2.2x
P/S Ratio-0.5x
P/E RatioIs ET8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ET8 income statement (TTM) | |
|---|---|
| Revenue | US$4.83m |
| Cost of Revenue | US$668.00k |
| Gross Profit | US$4.17m |
| Other Expenses | US$27.38m |
| Earnings | -US$23.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.18 |
| Gross Margin | 86.18% |
| Net Profit Margin | -480.12% |
| Debt/Equity Ratio | 0% |
How did ET8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 22:17 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
COSCIENS Biopharma Inc. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Loe | Byron Capital Markets |
| Douglas Loe | Cantor Fitzgerald Canada Corporation |
| Maher Yaghi | Desjardins Securities Inc. |